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Abstract
Background: Mental deficiency has been linked to abnormalities in cortical neuronal network connectivity and
plasticity. These mechanisms are in part under the control of two interacting signalling pathways, the serotonergic
and the brain-derived neurotrophic (BDNF) pathways. The aim of the current paper is to determine whether
particular alleles or genotypes of two crucial genes of these systems, the serotonin transporter gene (SLC6A4) and
the brain-derived neurotrophic factor gene (BDNF), are associated with mental deficiency (MD).
Methods: We analyzed four functional polymorphisms (rs25531, 5-HTTLPR, VNTR, rs3813034) of the SLC6A4 gene
and one functional polymorphism (Val66 Met) of the BDNF gene in 98 patients with non-syndromic mental
deficiency (NS-MD) and in an ethnically matched control population of 251 individuals.
Results: We found no significant differences in allele and genotype frequencies in the five polymorphisms studied
in the SLC6A4 and BDNF genes of NS-MD patients versus control patients. While the comparison of the patterns of
linkage disequilibrium (D’) in the control and NS-MD populations revealed a degree of variability it did not,
however, reach significance. No significant differences in frequencies of haplotypes and genotypes for VNTR/
rs3813034 and rs25531/5-HTTLPR were observed.
Conclusion: Altogether, results from the present study do not support a role for any of the five functional
polymorphisms of SLC6A4 and BDNF genes in the aetiology of NS-RM. Moreover, they suggest no epistatic
interaction in NS-MD between polymorphisms in BDNF and SLC6A4. However, we suggest that further studies on
these two pathways in NS-MD remain necessary.
Background
Mental deficiency (MD) is defined as an intelligence
quotient (IQ) below 70 with impairments in social skills,
self-care, and work. The prevalence of non-syndromic-
MD (NS-MD) in developed countries is higher than
0.5% [1,2]. A large proportion of NS-MD cases results
from abnormalities in neuronal network connectivity
and plasticity, and these require particular neurotrophic
factors and neurotransmitters for proper establishment
and functioning [3].
Serotonin (5-hydroxytryptamine, 5-HT) is a major
neurotransmitter involved in several complex beha-
viours, including cognition and emotion, which have
been shown to be altered in NS-MD [4]. Pharmacologi-
cal and genetic studies also support a role for serotonin
in corticogenesis, and brain development in general,
even prior to the formation of synapses [5-8]. One key
regulator of serotonin levels in the cortex and hippo-
campus is the serotonin transporter (5-HTT), which is
involved in the reuptake of extracellular serotonin
[9,10]. 5-HTT is a Na
+/Cl
- dependant membrane trans-
porter encoded by the SLC6A4 gene (solute carrier
family 6 member 4; 17q11.2) (Figure 1) [11]. A poly-
morphism (5HTTLPR) in the promoter region of
SLC6A4 determines the neuroanatomical size and func-
tional coupling of the amygdala-frontal cortical circuit
in humans [12,13]. This circuit has been implicated in
several psychiatric disorders including Fragile X and * Correspondence: vourch@med.univ-tours.fr
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mental deficiency [14,15].
The expression level of 5-HTT is affected by several
polymorphisms in the SLC6A4 gene (Figure 1). In the
promoter region, both the rs25531 polymorphism (SNP
A/G), which is part of a putative binding domain for the
AP2 transcription factor, and the 5HTTLPR polymorph-
ism (deletion/insertion) influence the expression levels
of 5HTT [16,17]. A neurophysiological imaging study in
humans described an association between 5-HTTLPR
and prefrontal cortex-limbic excitability, supporting a
relation between 5-HTT and cognitive processing
[18,19]. 5HTT expression can also be affected by a vari-
able number of tandem repeats (VNTR) in intron 2 and
a SNP (rs3813034) in the 3’UTR of the SLC6A4 gene
[20,21].
The function of 5HTT is modulated by brain-derived
neurotrophic factor (BDNF) as confirmed by experi-
ments on BDNF-deficient mice [22,23]. BDNF, a mem-
ber of the growth factor family of neurotrophins,
contributes to the activity-dependent synaptic develop-
ment and survival of serotonergic neurons [9,24]. In
general, BDNF is known to have crucial roles during
brain development as well as in adults by regulating
synaptic transmission and plasticity. Indeed, modulation
of BDNF expression in mice affects synaptic vesicle
functioning and plasticity, leading to defects in spatial
learning [25]. The secreted protein, BDNF, is encoded
by the BDNF gene located at 11p13 (Figure 1) [26]. The
SNP rs6255 (Val66 Met) in this gene affects the activity-
dependent secretion of BDNF as well as short-term epi-
sodic memory in humans [27,28].
When combined with the observation of abnormal
serotonin and BDNF blood concentrations in several
subjects with NS-MD, the evidence presented thus far
suggets that the serotonergic and BDNF signalling sys-
tems may be implicated in the aetiology of NS-MD
[29-31]. We therefore tested this hypothesis by analysing
five functional polymorphisms in the SLC6A4 and BDNF
genes in patients with NS-MD.
Methods
Subjects
The patients with NS-MD (n = 98; 77 males and 21
females) were recruited in the genetics unit of the Uni-
versity hospital in Tours (France). All patients showed
moderate to severe NS-MD and were submitted to a
careful clinical examination, searching for specific signs
of the NS-MD syndrome. The patients had no familial
history of MD and were therefore considered sporadic.
All were negative for fragile X mutation (FRAXA). The
control group (n = 251) consisted of anonymous and
unrelated French Caucasian individuals without MD.
DNA was extracted from peripheral blood sample using
a standard protocol. All patients or parents gave their
informed consent.
Genotyping
The rs25531 and 5-HTTLPR in SLC6A4 were analyzed
by RFLP as described in Wendland et al. [32]. The PCR
amplification step allowed to differentiate between the
short (S, 484 bp) versus the long allele (L, 528 bp) of 5-
HTTLPR. The restriction step using HpaII enzyme (Bio-
labs) permitted to identify the alleles (A/G) of rs25531,
located 19 bp upstream of 5 - H T T L P R .T h u s ,1 0p a t -
terns of migration corresponding to 10 genotypes
(rs25531/5-HTTLPR) could be identified after electro-
phoresis on a 2% agarose gel (all primers and conditions
are available upon request).
The VNTR (17 bp variable number of tandem repeats)
in SLC6A4 was studied by PCR followed by electrophor-
esis on 3% agarose gel stained with ethidium bromide.
PCR conditions for the amplification of the 9 (345 bp),
10 (360 bp) and 12 (390 bp) repeat alleles are described
in Cook et al. [33].
The rs3813034 (G/T) in the 3’UTR region of SLC6A4
gene was genotyped by RFLP. PCR was performed on
100 ng of genomic DNA with 125 μM of each dNTP,
2 0 0n Mo fp r i m e r s ,1 . 5m MM g C l 2 and 0.02 U/μLo f
Taq DNA polymerase (Invitrogen), before incubation
with MseI (Fermentas) and electrophoresis on a 2%
agarose gel.
The rs6255 (G/A) in BDNF was studied by denaturing
high performance liquid chromatography (dHPLC,
WAVE System 3500 HT, Transgenomic). PCR was per-
formed on 100 ng of genomic DNA with 125 μMo f
each dNTP, 200 nM of primers, 1.5 mM MgCl2 and
0.02 U/μL of Taq DNA polymerase (Invitrogen) (Tm:
59°C). PCR products were denaturated (96°C 5 min) and
slowly renaturated (96°C to 50°C; 1°C/minute) before
analysis by dHPLC at 60.2°C. For individuals showing
Figure 1 Schematic structure of the human SLC6A4 (A) and
BDNF (B) genes. Non-coding and coding exons are indicated by
white and black boxes, respectively. Locations of the genotyped
polymorphisms and alternative splicing are indicated.
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gotes), 10 μLo fP C Rw e r em i x e dw i t h1 0μLo faP C R
product (standard) previously analyzed by DNA sequen-
cing (G/G homozygote). The mixture was denaturated,
renaturated, and analysed by dHPLC.
Statistical analysis
Allele and genotype frequencies in patients and controls
were compared with a c
2 t e s t .O d d sr a t i o sw e r ee s t i -
mated for alleles and genotypes http://www.hutchon.
net/ConfidOR.htm[34]. Linkage disequilibrium (para-
meter D’) between markers was calculated using the
software Haploview v.3.32, with the exception of
rs25531 and 5HTTLPR polymorphisms for which chro-
mosome phases could be obtained directly. LD patterns
were analysed by Spearman rank correlation (Excel)
between LD measures.
Results
Analysis of SLC6A4 polymorphisms in NS-MD
Hardy Weinberg distribution was respected for the four
polymorphisms in SLC6A4 in the two populations (not
shown). We did not observe a significant association
between NS-MD and the rs25531 (c
2 = 0.98; p = 0.32),
5-HTTLPR (c
2 = 0.07; p = 0.79) VNTR (c
2 =0 . 5 1 ;
p = 0.47), and rs3813034 (c
2 = 0.69; p = 0.40) alleles
(Figure 1; table 1). Similarly, no significant association
was detected between NS-MD and the genotypes of the
four polymorphisms (data not shown). The genotyping
method used for rs25531 (AP2) and 5-HTTLPR per-
mitted a direct identification of the phased genotypes.
Using these phased genotypes, no significant association
between NS-MD and a particular haplotype (c
2 =0 . 9 9 ;
p = 0.61) or genotype (c
2 = 1.13; p = 0.77) was detected.
As Hu et al. (2006) reported that the GL genotype can
drive 5HTT expression nearly equivalently to any S gen-
otype (AS or GS), we consequently grouped the GL, AS,
and GS haplotypes for analysis. However we still did not
observe an association between NS-MD and the haplo-
type (c
2 = 0,12; p = 0.73) or genotype (c
2 =1 . 2 8 ;p=
0.73) (Table 2). We used pairwise LD measures (D’)
between adjacent markers to analyse the patterns of LD
in the control and NS-MD populations (Figure 2). Com-
parison of these unrelated populations revealed a degree
of variability which, however, did not reach significance
(Spearman rank correlation, rs = 0.50; p = 0.66). We
next analyzed the VNTR/rs3813034 haplotypes in the
two populations, and again found no significant differ-
ence for haplotype (c
2 = 3.80; p = 0.28) and genotype
(c
2 = 3.50; p = 0.75) distributions between controls and
NS-MD patients (Table 3).
Analysis of the BDNF Val66 Met polymorphism in NS-MD
Hardy Weinberg distribution was respected for the
alleles of the BDNF gene in the two populations. We
developed a rapid genotyping method using dHPLC to
analyze the allelic distribution of the rs6255 (Val66 Met)
polymorphism in the BDNF gene (Figure 1). A first ana-
lysis by dHPLC allowed to identify the heterozygote
genotypes (G/A), and a second analysis, in presence of a
standard, allowed to discriminate between G/G or A/A
homozygotes. We did not find a significant association
between NS-MD and alleles of the rs6255 polymorph-
ism (c
2 = 0.40; p = 0.53) (Table 1).
Several studies have suggested a synergistic interaction
between the serotonergic and the BDNF signalling
Table 1 Allelic distributions of polymorphisms in SLC6A4
and BDNF genes in the control and NS-MD populations.
Markers Alleles Controls MR patients MR vs Controls
c
2 p
SLC6A4 gene
rs25531 A 308 (93.9) 188 (95.9) 0.98 0.32
G 20 (6.1) 8 (4.1)
5-HTTLPR L 198 (60.4) 116 (59.2) 0.07 0.79
S 130 (39.6) 80 (40.8)
VNTR 9 4 (1.2) 2 (1.0) 0.60 0.74
10 113 (34.5) 74 (37.8)
12 211 (64.3) 120 (61.2)
rs3813034 T 187 (57.0) 119 (60.7) 0.69 0.40
G 141 (43.0) 77 (39.3)
BDNF gene
rs6255 G 378 (75.2) 129 (77.7) 0.40 0.53
A 124 (24.8) 37 (22.3)
Table 2 Haplotypes and phased genotypes distributions
for the rs25531 and 5-HTTLPR polymorphisms in the
SLC6A4 gene in control and NS-MD populations.
AP2, 5-HTTLPR Controls MR patients MR vs Controls
c
2 p
Haplotypes (5HTT gene)
AL 179 (54.57) 110 (56,12) 0.12 0.73
AS, GL, GS 149 (45.43) 86 (43,88)
Phased genotypes (5HTT gene)
AL/AL 45 (27.44) 28 (28.57) 1.28 0.73
AL/AS 73 (44.51) 47 (47.96)
AL/GL 16 (9.76) 6 (6.12)
AL/GS 0 (0.0) 1 (1.02)
Others 30 (18.29) 16 (16.33)
Genotypes (5HTT/BDNF genes)
AL AL/Val Val 19 (13.00) 10 (12.66) 0.65 0.88
AL AL/Val Met 21 (14.40) 11 (13.92)
Others/Val Val 59 (40.40) 36 (45.57)
Others/Val Met 47 (32.20) 22 (27.85)
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between NS-MD and the 5HTTLPR/rs6255, rs25531
(AP2)/rs6255, or rs3813034/rs6255 genotypes (data not
shown). No association was found between NS-MD and
a particular combination of AP2-5HTTLPR (AL or
o t h e r s )o ft h eS L C 6 A 4g e n ea n dr s 6 2 5 5( Ao rG )o ft h e
BDNF gene.
Discussion
We here report the first genetic study on the serotonin
transporter and the brain-derived neurotrophic factor
g e n e si nN S - M D .W eh a v ei n v e s t i g a t e df i v ef u n c t i o n a l
polymorphisms in these genes in control individuals and
NS-MD patients matched for origin (Central France)
and ethnicity (Caucasian).
Power calculations had shown that with the given
sample sizes we should be able to detect differences in
allelic frequencies of 12% for 5-HTTLPR, 12% for
VNTR, 13% for rs3813034, and 10% for BDNF rs6255
(alpha of 5%, power of 80%). Functional studies have
reported that the S allele of 5-HTTLPR was associated
with a lower expression of 5-HTT and a lower serotonin
reuptake activity [12,36,37]. Our results do not support
a direct role for the S allele of 5-HTTLPR in NS-MD.
Wendland et al. [32] suggested that the effect of 5-
HTTLPR on SLC6A4 expression may be due to a nearby
(19 bp) rs25531 polymorphism in the promoter. The G
allele of this polymorphism is located in a consensus
binding site for AP2, a family of transcription factors
described as positive or negative regulators of transcrip-
tion [38]. Data from Hu and colleagues [39] has shown
that the G allele of rs25531 was associated with a
decreased expression of 5-HTT mRNA compared to the
A allele. We did not detect differences in rs25531 allelic
frequencies between NS-MD and control patients.
Moreover, we have observed that the frequency of the
GS haplotype in both NS-MD and control patients was
very low, suggesting that the G allele of rs25531 was not
a risk factor for NS-MD. No statistically significant dif-
ference was observed between control and NS-MD
patients for genotypes and allelic distributions of the
VNTR and rs3813034.
Brain-derived neurotrophic factor (BDNF) is a key
regulatory protein of serotonin levels in several brain
regions. The pro-BDNF protein is cleaved to form a
mature protein before being secreted. The rs6255 poly-
morphism (Val66 Met), which affects this cleavage, has
been associated with impaired hippocampal function-
ing and decreased scores on the Logical Memory subt-
est of the Wechsler Memory Scale-Revised [28].
Moreover, Harris et al. [40] have shown that the
rs6255 genotype contributes to age-related changes in
reasoning skills, which are closely related to general
intelligence. Thus, a number of studies support an
Table 3 Haplotypes and genotypes distributions for the
VNTR and rs3813034 polymorphisms in the SLC6A4 gene
in controls and NS-MD patients.
VNTR, rs3813034 Controls MR patients MR vs Controls
c
2 p
Haplotypes
12G 125 (38.1) 70 (35.7) 3.8 0.28
12T 85 (25.9) 48 (24.5)
10T 99 (30.2) 72 (36.7)
Others 19 (5.8) 6 (3.1)
Genotypes
12G/10T 38 (23.0) 26 (26.2) 3.5 0.75
12G/12T 32 (19.8) 17 (17.6)
12G/12G 24 (14.5) 13 (12.9)
12T/10T 26 (15.7) 17 (17,8)
12T/12T 11 (6.7) 6 (5.99)
10T/10T 15 (9.1) 13 (13.3)
Others 18 (11.2) 6 (6.1)
Figure 2 Linkage disequilibrium (LD) map of four polymorphic
markers in SLC6A4 gene in control and NS-MD patients.I n
each square, the normalized linkage disequilibrium measures (D’)
corresponding to each pair of markers are indicated. Squares are in
black if the D’ values are ≥ 80% (strong LD) and in grey if the D’
values are between 50-80%.
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particularly in learning and memory. We did not
observe an association between a particular allele or a
genotype of rs6255 and French patients with NS-MD.
However, it will be interesting to further analyze the
complex BDNF locus in neurodevelopmental diseases
such as NS-MD. Indeed, recent studies, which have
reported a detailed characterization of the BDNF gene
locus, have indicated 17 and 13 alternative transcripts
for BDNF and anti-BDNF, respectively [41]. Anti-
BDNF are antisense transcripts expressed from the
opposite strand of the BDNF gene [26].
Serotonergic and BDNF signalling systems have signif-
icant interactions with overlapping functional targets
[30]. Genetic epistasis between these two systems was
confirmed by studies on BDNF and SLC6A4 transgenic
mice [23,24]. In the present study on NS-MD patients
we observed no genetic interactions between Val66 Met
in BDNF and the four polymorphisms studied in
SLC6A4. Particularly, we did not find a relation between
the Met allele in BDNF and the S allele in SLC6A4, as
described in children with high depressive scores [42].
However, these latter results obtained by Kauffman et
al. [42] have been challenged by several studies report-
ing that the Met allele is protective for anxiety and
depression [43,44].
Conclusion
The present study suggests that the SLC6A4 and BDNF
genes have no major effect on the aetiology of NS-MD.
Moreover we did not find a gene-by-gene interaction in
NS-MD patients between polymorphisms in the BDNF
and SLC6A4 genes. However, further studies will be
necessary to fully reject the implication of SLC6A4 and
BDNF in NS-MD. Indeed the expression of these two
genes is regulated by epigenetic processes, and these
may still be impaired in NS-MD [45,46]. Moreover,
effects on mRNA splicing, protein localization, and
properties of 5-HTT and BDNF could be possible
mechanisms for influencing NS-MD risk.
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